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Editorial Comment 
Why Do Beta-Receptor Blockers 
Decrease Mortality After 
Myocardial Infarction? * 
EDGAR LICHSTEIN, MD, FACC 
Brooklyn, New York 
Review of major studies. Beta-blockers decrease mor•
tality after myocardial infarction. This statement is no longer 
controversial after publication of several large well con•
trolled studies (1-4). Yusuf et al. (5) in an extensive review 
concluded that all available data support the conclusion that 
beta-adrenergic blocking agents decrease mortality, the in•
cidence of nonfatal reinfarction and sudden death after in•
farction. The questions that remain concern the mechanism 
of action and whether this is a class action of all beta•
blockers. Singh and Venkatesh (6) suggested that the drugs 
with significant intrinsic agonist activity such as pindolol 
and oxprenolol might be less effective. The European In•
farction Study (7,8) with oxprenolol is one of the few recent 
negative studies. This study was stopped prematurely be•
cause of a nonstatistically significant increase in mortality 
in the study group. The reasons for this trend may include 
fault in the study design or the degree of intrinsic agonist 
activity in the drug being studied. This negative study is 
the basis of the arrhythmia analysis presented by Bethge et 
al. (8) for the European Infarction Study Group in this issue 
of the Journal. 
Explanations of decreased mortality. The major causes 
of death after myocardial infarction include recurrent isch•
emia, arrhythmia and left ventricular dysfunction (9). It may 
be difficult, if not impossible, to separate the effects of 
ischemia from arrhythmia in the postinfarction patient. 
Stimulation of beta-receptor blocking agents by catechol•
amines increases myocardial oxygen consumption and may 
increase ischemia (10). Obviously, drugs that block the beta•
receptors reduce the effects of these catecholamines by de•
creasing systemic blood pressure, heart rate and myocardial 
contractility. Other less well documented effects include 
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those on the coronary microvasculature, collateral blood 
flow and platelet function (10). The incidence of nonfatal 
reinfarction was significantly reduced in the timolol trial (3) 
and a trend toward lower rates of reinfarction was found in 
the other major trials. These data suggest that postinfarction 
mortality might be reduced through an effect on ischemia 
(9). Data pooled from seven of the major trials revealed that 
beta-blockers caused a 28% reduction in mortality and a 
33% reduction in sudden cardiac death. These figures sug•
gest a primary antiarrhythmic effect as the major cause of 
beneficial action (10). Cyclic adenosine monophosphate 
(AMP), which accumulates in ischemic zones of experi•
mental myocardial infarction, is arrhythmogenic and its oc•
currence may be prevented by beta-blockade (II). 
Postinfarction ventricular arrhythmia is a well docu•
mented marker of increased mortality. Although it is dif•
ficult to separate ventricular function from ventricular ar•
rhythmia, it does appear that complex ventricular arrhythmia 
is an independent marker of mortality (12-14). 
Decrease in ventricular arrhythmia shown by several 
beta-blocker studies. It is clear that beta-blockers have an 
effect on ventricular arrhythmia in the post-myocardial in•
farction patient. Koppes et al. (15) noted that 160 mg of 
propranolol daily reduced the frequency and complexity of 
ventricular premature beats after myocardial infarction. The 
Beta Blocker Heart Attack Trial (BHA T) studied ventricular 
arrhythmia by performing Holter electrocardiographic re•
cordings on all patients at baseline (5 to 21 days after hos•
pital admission) and then on a subgroup of 25% of patients 
at 6 weeks (\6). At 6 weeks, the untreated control group 
showed an increased prevalence of ventricular arrhythmia, 
but this increase was blunted in the group taking propran•
olol. Studies with atenolol showed a decrease in ventricular 
arrhythmia and specifically a reduction of the R on T phe•
nomenon and repetitive beats (17). Studies by Olsson and 
Rehnqvist (18) and Cats et al. (19) with metoprolol noted 
an increase in the frequency and complexity of ventricular 
premature beats after myocardial infarction. This was coun•
teracted but not abolished by metoprolol. The arrhythmia 
analysis in the metoprolol study performed by Ryden et al. 
(20) showed no effect on the occurrence of ventricular pre•
mature beats or short bursts of ventricular tachycardia. How•
ever, a very striking and important finding was an effect on 
ventricular fibrillation. The study by Bethge et al. (8) did 
not find a significant antiarrhythmic effect when oxprenolol, 
320 mg daily, was compared with placebo. The only effect 
noted was a significant decrease in multiform ventricular 
extrasystoles in the treatment group at 3 and 6 months. A 
major problem in interpreting these data is the study design, 
in which only a small percent of the total group had Holter 
electrocardiographic recordings. A significant number of 
recordings could not be completed for technical or admin-
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istrat\ve reasons, and many were not available because of 
the lack of patient cooperation or lack of resources at the 
study hospital. This raises the possibility that some type of 
bias may have been introduced into the study. Another pos•
sible explanation for this negative result is the drug itself. 
Oxprenolol, which has intrinsic agonist activity, was also 
shown to have no detectable antiarrhythmic effect in a trial 
performed by Wilcox et al. (21). 
Does decrease in ventricular arrhythmia explain de•
crease in mortality? Complex ventricular premature beats 
are associated witli increased mortality and it is generally 
recognized that many of the beta-blockers decrease these 
ventricular arrhythmias. It therefore seems reasonable to 
hypothesize that this antiarrhythmic effect is the mechanism 
by which the beta-blockers decrease mortality. Capone et 
al. (22) studied this in the BHAT population. They found 
that patients with complex ventricular premature beats did 
have a higher mortality but benefited to the same relative 
degree from propranolol as did those without complex ar•
rhythmia. Thus, propranolol did not provide any special 
benefit to those with complex ventricular ectopic rhythm. 
Primary effect on ventricular fibrillation. The effect 
of beta-blockers on ventricular fibrillation has been noted 
for many years. Recently, Anderson et al. (23) demonstrated 
an increase in ventricular fibrillation threshold with five 
different beta-blockers using the anesthetized open chest dog 
model. They found a further increase in fibrillation threshold 
after bilateral stellate ganglionectomy. This further shows 
the dependence of ventricular fibrillation threshold on car•
diac sympathetic stimulation. The authors tested five beta•
blockers with significant differences in their special prop•
erties. Membrane effect and cardioselectivity did not appear 
to alter results. In low doses, pindolol, a drug with agonist 
activity, had less effect on ventricular fibrillation threshold 
compared with timolol. This may be consistent with the 
observations of Kramer et al. (24), who showed an adverse 
effect of intrinsic sympathomimetic activity on ventricular 
fibrillation. The partial agonist activity of pindolol is similar 
to that of oxprenolol and may provide an explanation of the 
negative effects on mortality seen in the European Infarction 
Study. Two of the large beta-blocker studies have provided 
interesting information concerning ventricular fibrillation that 
may, in part, explain the mortality results. A subgroup anal•
ysis of the BHAT data (25) revealed a lower mortality rate 
in patients treated with propranolol who had had electrical 
complications including prior ventricular fibrillation. The 
metoprolol study (20) showed no effect on ventricular pre•
mature beats but a significant effect in preventing ventricular 
fibrillation. These studies indicate that an antifibrillatory 
effect may be seen when an antiectopic effect is not. It is 
possible that microreentry, which is necessary for ventric•
ular fibrillation, may be prevented in situations in which 
macroreentry, which is necessary for ventricular premature 
beats, is not prevented (26). 
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Conclusions. The effect of the beta-blockers on ven•
tricular premature beats, while present, is weak and prob•
ably does not explain the drug's beneficial effect on mor•
tality. The effect on ventricular fibrillation threshold is different 
from the effect on ectopic beats and is the more likely 
explanation of the increased survival. It would be of interest 
if the data of the European Infarction Study and the other 
large beta-blocker studies were examined for effects on ven•
tricular fibrillation. 
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